

Protalix BioTherapeutics, Inc.  
Form 8-K  
January 14, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 14, 2010 (January 13, 2010)**

**Protalix BioTherapeutics, Inc.  
(Exact name of registrant as specified in its charter)**

<b>Florida</b> <b>(State or other jurisdiction of incorporation)</b>	<b>000-33357</b> <b>(Commission File Number)</b>	<b>65-0643773</b> <b>(IRS Employer Identification No.)</b>
<b>2 Snunit Street</b> <b>Science Park, POB 455</b> <b>Carmiel, Israel</b> <b>(Address of principal executive offices)</b>		<b>20100</b> <b>(Zip Code)</b>
	<b>Registrant's telephone number, including area code +972-4-988-9488</b> <b>(Former name or former address, if changed since last report.)</b>	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 2(b)
  - Pre-commencement communications pursuant to Rule 4(c)
-

**Item 8.01. Other Events**

On January 13, 2010, the Company issued a press release announcing that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), after reviewing all relevant clinical data, has recommended that the European Commission grant orphan drug designation to taliglucerase alfa, the Company's proprietary plant cell expressed recombinant form of glucocerebrosidase for the treatment of Gaucher disease. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated January 13, 2010.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: January 14, 2010

By: /s/ David Aviezer  
Name: David Aviezer, Ph.D.  
Title: President and  
Chief Executive Officer